Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization

被引:176
作者
Hsieh, JJD
Ernst, P
Erdjument-Bromage, H
Tempst, P
Korsmeyer, SJ
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst,Howard Hughes Med Inst, Dept Pathol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst,Howard Hughes Med Inst, Dept Med, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA
关键词
D O I
10.1128/MCB.23.1.186-194.2003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mixed-lineage leukemia gene (MLL, ALL1, HRX) encodes a 3,969-amino-acid nuclear protein homologous to Drosophila trithorax and is required to maintain proper Hox gene expression. Chromosome translocations in human leukemia disrupt MLL (11q23), generating chimeric proteins between the N terminus of MLL and multiple translocation partners. Here we report that MLL is normally cleaved at two conserved sites (D/GADD and D/GVDD) and that mutation of these sites abolishes the proteolysis. MLL cleavage generates N-terminal p320 (N320) and C-terminal p180 (C180) fragments, which form a stable complex that localizes to a subnuclear compartment. The FYRN domain of N320 directly interacts with the FYRC and SET domains of C180. Disrupting the interaction between N320 and C180 leads to a marked decrease in the level of N320 and a redistribution of C180 to a diffuse nuclear pattern. These data suggest a model in which a dynamic post-cleavage association confers stability to N320 and correct nuclear sublocalization of the complex, to control the availability of N320 for target genes. This predicts that MLL fusion proteins of leukemia which would lose the ability to complex with C180 have their stability conferred instead by the fusion partners, thus providing one mechanism for altered target gene expression.
引用
收藏
页码:186 / 194
页数:9
相关论文
共 36 条
[1]   MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia [J].
Armstrong, SA ;
Staunton, JE ;
Silverman, LB ;
Pieters, R ;
de Boer, ML ;
Minden, MD ;
Sallan, SE ;
Lander, ES ;
Golub, TR ;
Korsmeyer, SJ .
NATURE GENETICS, 2002, 30 (01) :41-47
[2]   Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins [J].
Ayton, PM ;
Cleary, ML .
ONCOGENE, 2001, 20 (40) :5695-5707
[3]  
BREEN TR, 1993, DEVELOPMENT, V117, P119
[4]   The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures [J].
Butler, LH ;
Slany, R ;
Cui, XM ;
Cleary, ML ;
Mason, DY .
BLOOD, 1997, 89 (09) :3361-3370
[5]   The amino terminus of the mixed lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation [J].
Caslini, C ;
Shilatifard, A ;
Yang, LP ;
Hess, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) :2797-2802
[6]   BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis [J].
Cheng, EHYA ;
Wei, MC ;
Weiler, S ;
Flavell, RA ;
Mak, TW ;
Lindsten, T ;
Korsmeyer, SJ .
MOLECULAR CELL, 2001, 8 (03) :705-711
[7]   An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes [J].
Corral, J ;
Lavenir, I ;
Impey, H ;
Warren, AJ ;
Forster, A ;
Larson, TA ;
Bell, S ;
McKenzie, ANJ ;
King, G ;
Rabbitts, TH .
CELL, 1996, 85 (06) :853-861
[8]   A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins [J].
Cross, SH ;
Meehan, RR ;
Nan, XS ;
Bird, A .
NATURE GENETICS, 1997, 16 (03) :256-259
[9]   Association of SET domain and myotubularin-related proteins modulates growth control [J].
Cui, XM ;
De Vivo, I ;
Slany, R ;
Miyamoto, A ;
Firestein, R ;
Cleary, ML .
NATURE GENETICS, 1998, 18 (04) :331-337
[10]   Tumorigenesis in mice with a fusion of the leukaemia oncogene MII and the bacterial lacZ gene [J].
Dobson, CL ;
Warren, AJ ;
Pannell, R ;
Forster, A ;
Rabbitts, TH .
EMBO JOURNAL, 2000, 19 (05) :843-851